Dulaglutid (Slovenian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Dulaglutid" in Slovenian language version.
refsWebsite
Global rank
Slovenian rank
11th place
51st place
1st place
2nd place
719th place
152nd place
low place
34th place
low place
4,177th place
diabetesjournals.org
care.diabetesjournals.org
- Nauck M, Weinstock RS, Umpierrez GE, in sod. (Avgust 2014). »Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)«. Diabetes Care. 37 (8): 2149–58. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660. Pridobljeno 1. marca 2015.
doi.org
- Tibble CA, Cavaiola TS, Henry RR (Maj 2013). »Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes: A Review of Current Literature«. Expert Rev Endocrinol Metab. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
- Terauchi Y, Satoi Y, Takeuchi M, in sod. (Julij 2014). »Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study«. Endocr. J. 61 (10): 949–59. doi:10.1507/endocrj.ej14-0147. PMID 25029955.
- Nauck M, Weinstock RS, Umpierrez GE, in sod. (Avgust 2014). »Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)«. Diabetes Care. 37 (8): 2149–58. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660. Pridobljeno 1. marca 2015.
- Amblee A (april 2014). »Dulaglutide for the treatment of type 2 diabetes«. Drugs Today. 50 (4): 277–289. doi:10.1358/dot.2014.50.4.2132740. PMID 24918645.
{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) - Monami M, Dicembrini I, Nardini C, in sod. (Februar 2014). »Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials«. Diabetes Res. Clin. Pract. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
- Nadkarni P, Chepurny OG, Holz GG (2014). »Regulation of glucose homeostasis by GLP-1«. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus. Prog Mol Biol Transl Sci. Progress in Molecular Biology and Translational Science. Zv. 121. str. 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 9780128001011. PMC 4159612. PMID 24373234.
drugs.com
- »Dulaglutide (Trulicity) Use During Pregnancy«. Drugs.com. 15. julij 2019. Pridobljeno 4. februarja 2020.
- »Dulaglutide international«. Drugs.com. 3. januar 2020. Pridobljeno 4. februarja 2020.
europa.eu
ema.europa.eu
- https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Trulicity, vpogled: 23. 3. 2023.
- »Trulicity EPAR«. Evropska agencija za zdravila (EMA). 17. september 2018. Pridobljeno 23. februarja 2020.
fda.gov
fda.gov
- »FDA approves Trulicity to treat type 2 diabetes« (tiskovna objava). Ameriški Urad za hrano in zdravila (FDA). 18. september 2014. Arhivirano iz prvotnega spletišča dne 20. aprila 2016. Pridobljeno 4. februarja 2020.
Članek vsebuje besedilo iz tega vira, ki je v javni domeni. - »Risk Evaluation and Mitigation Strategy (REMS)«. United States Food and Drug Administration. september 2014. Pridobljeno 24. marca 2020.
{{navedi splet}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
accessdata.fda.gov
- »Drug Approval Package: Trulicity (dulaglutide) NDA #125469«. Ameriški Urad za hrano in zdravila (FDA). 27. oktober 2014. Pridobljeno 4. februarja 2020.
lilly.com
investor.lilly.com
- »Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes« (tiskovna objava). Eli Lilly. 25. februar 2014.
medscape.com
- Tibble CA, Cavaiola TS, Henry RR (Maj 2013). »Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes: A Review of Current Literature«. Expert Rev Endocrinol Metab. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Tibble CA, Cavaiola TS, Henry RR (Maj 2013). »Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes: A Review of Current Literature«. Expert Rev Endocrinol Metab. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
- Terauchi Y, Satoi Y, Takeuchi M, in sod. (Julij 2014). »Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study«. Endocr. J. 61 (10): 949–59. doi:10.1507/endocrj.ej14-0147. PMID 25029955.
- Nauck M, Weinstock RS, Umpierrez GE, in sod. (Avgust 2014). »Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)«. Diabetes Care. 37 (8): 2149–58. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660. Pridobljeno 1. marca 2015.
- Amblee A (april 2014). »Dulaglutide for the treatment of type 2 diabetes«. Drugs Today. 50 (4): 277–289. doi:10.1358/dot.2014.50.4.2132740. PMID 24918645.
{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) - Monami M, Dicembrini I, Nardini C, in sod. (Februar 2014). »Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials«. Diabetes Res. Clin. Pract. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
- Nadkarni P, Chepurny OG, Holz GG (2014). »Regulation of glucose homeostasis by GLP-1«. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus. Prog Mol Biol Transl Sci. Progress in Molecular Biology and Translational Science. Zv. 121. str. 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 9780128001011. PMC 4159612. PMID 24373234.
ncbi.nlm.nih.gov
- Nauck M, Weinstock RS, Umpierrez GE, in sod. (Avgust 2014). »Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)«. Diabetes Care. 37 (8): 2149–58. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660. Pridobljeno 1. marca 2015.
- Nadkarni P, Chepurny OG, Holz GG (2014). »Regulation of glucose homeostasis by GLP-1«. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus. Prog Mol Biol Transl Sci. Progress in Molecular Biology and Translational Science. Zv. 121. str. 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 9780128001011. PMC 4159612. PMID 24373234.
semanticscholar.org
api.semanticscholar.org
- Tibble CA, Cavaiola TS, Henry RR (Maj 2013). »Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes: A Review of Current Literature«. Expert Rev Endocrinol Metab. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
- Monami M, Dicembrini I, Nardini C, in sod. (Februar 2014). »Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials«. Diabetes Res. Clin. Pract. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
termania.net
- https://www.termania.net/slovarji/slovenski-medicinski-slovar/9942553/dulaglutid?query=Dulaglutid&SearchIn=All Slovenski medicinski e-slovar, vpogled: 23. 3. 2023.
web.archive.org
- »FDA approves Trulicity to treat type 2 diabetes« (tiskovna objava). Ameriški Urad za hrano in zdravila (FDA). 18. september 2014. Arhivirano iz prvotnega spletišča dne 20. aprila 2016. Pridobljeno 4. februarja 2020. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.